All‐cause mortality · adults undergoing cardiac surgery with cardiopulmonary bypass
It is very uncertain whether high changes all‐cause mortality compared with low blood pressure target (very low certainty).
1 finding from 1 review
All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low long‐chain omega‐3 fats (high certainty).
1 finding from 1 review
All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low alpha‐linolenic acid omega‐3 fats (moderate certainty).
1 finding from 1 review
All‐cause mortality · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention showed no clear difference in all‐cause mortality (high certainty).
1 finding from 1 review
All‐cause mortality · people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease or at high risk of atherothrombotic disease
clopidogrel plus aspirin showed no clear difference in all‐cause mortality compared with aspirin alone (low certainty).
1 finding from 1 review
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in mortality (all‐cause) compared with any control treatment (moderate certainty).
1 finding from 1 review